The authors tested SARS-CoV-2-specific T-cell (CοV-2-ST) immunity and expansion in unexposed donors, COVID-19 infected individuals, asymptomatic PCR-positive subjects, vaccinated individuals, non-ICU hospitalized patients and ICU patients.
[Clinical Infectious Diseases]
6445218
{6445218:WZHF4GJC}
apa
50
1
161723
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-8474a92100ac81a93946923c99dd8042%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WZHF4GJC%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Papayanni%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPapayanni%2C%20P.-G.%2C%20Chasiotis%2C%20D.%2C%20Koukoulias%2C%20K.%2C%20Georgakopoulou%2C%20A.%2C%20Iatrou%2C%20A.%2C%20Gavriilaki%2C%20E.%2C%20Giannaki%2C%20C.%2C%20Bitzani%2C%20M.%2C%20Geka%2C%20E.%2C%20Tasioudis%2C%20P.%2C%20Chloros%2C%20D.%2C%20Fylaktou%2C%20A.%2C%20Kioumis%2C%20I.%2C%20Triantafyllidou%2C%20M.%2C%20Dimou-Besikli%2C%20S.%2C%20Karavalakis%2C%20G.%2C%20Boutou%2C%20A.%20K.%2C%20Siotou%2C%20E.%2C%20Anagnostopoulos%2C%20A.%2C%20%26%23x2026%3B%20Yannaki%2C%20E.%20%282021%29.%20Vaccinated%20and%20convalescent%20donor-derived%20SARS-CoV-2-specific%20T%20cells%20as%20adoptive%20immunotherapy%20for%20high-risk%20COVID-19%20patients.%20%3Ci%3EClinical%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3Eciab371%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab371%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab371%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DWZHF4GJC%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Vaccinated%20and%20convalescent%20donor-derived%20SARS-CoV-2-specific%20T%20cells%20as%20adoptive%20immunotherapy%20for%20high-risk%20COVID-19%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Penelope-Georgia%22%2C%22lastName%22%3A%22Papayanni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitrios%22%2C%22lastName%22%3A%22Chasiotis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiriakos%22%2C%22lastName%22%3A%22Koukoulias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aphrodite%22%2C%22lastName%22%3A%22Georgakopoulou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastasia%22%2C%22lastName%22%3A%22Iatrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleni%22%2C%22lastName%22%3A%22Gavriilaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chrysavgi%22%2C%22lastName%22%3A%22Giannaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Militsa%22%2C%22lastName%22%3A%22Bitzani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleni%22%2C%22lastName%22%3A%22Geka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Polychronis%22%2C%22lastName%22%3A%22Tasioudis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diamantis%22%2C%22lastName%22%3A%22Chloros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asimina%22%2C%22lastName%22%3A%22Fylaktou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannis%22%2C%22lastName%22%3A%22Kioumis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Triantafyllidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotiria%22%2C%22lastName%22%3A%22Dimou-Besikli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgios%22%2C%22lastName%22%3A%22Karavalakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afroditi%20K%22%2C%22lastName%22%3A%22Boutou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleni%22%2C%22lastName%22%3A%22Siotou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Achilles%22%2C%22lastName%22%3A%22Anagnostopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastasia%22%2C%22lastName%22%3A%22Papadopoulou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evangelia%22%2C%22lastName%22%3A%22Yannaki%22%7D%5D%2C%22abstractNote%22%3A%22Severe%20acute%20respiratory%20syndrome%20coronavirus-2%20%28SARS-CoV-2%29%20pandemic%20poses%20an%20urgent%20need%20for%20the%20development%20of%20effective%20therapies%20for%20Coronavirus%20Disease%202019%20%28COVID-19%29.We%20first%20tested%20SARS-CoV-2-specific%20T-cell%20%28C%5Cu03bfV-2-ST%29%20immunity%20and%20expansion%20in%20unexposed%20donors%2C%20COVID-19%20infected%20individuals%20%28convalescent%29%2C%20asymptomatic%20PCR-positive%20subjects%2C%20vaccinated%20individuals%2C%20non-ICU%20hospitalized%20patients%20and%20ICU%20patients%20who%20either%20recovered%20and%20were%20discharged%20%28ICU%20recovered%29%20or%20had%20a%20prolonged%20stay%20and%5C%2For%20died%20%28ICU%20critical%29.%20CoV-2-STs%20were%20generated%20from%20all%20types%20of%20donors%20and%20underwent%20phenotypic%20and%20functional%20assessment.We%20demonstrate%20causal%20relationship%20between%20the%20expansion%20of%20endogenous%20CoV-2-STs%20and%20the%20disease%20outcome%3B%20insufficient%20expansion%20of%20circulating%20CoV-2-STs%2C%20identified%20hospitalized%20patients%20at%20high-risk%20for%20an%20adverse%20outcome.%20CoV-2-STs%20with%20a%20similarly%20functional%20and%20non-alloreactive%2C%20albeit%20highly%20cytotoxic%2C%20profile%20against%20SARS-CoV-2%20could%20be%20expanded%20from%20both%20convalescent%20and%20vaccinated%20donors%20generating%20clinical-scale%2C%20SARS-CoV-2-specific%20T-cell%20products%20with%20functional%20activity%20against%20both%20the%20unmutated%20virus%20and%20its%20B.1.1.7%20variant.%20In%20contrast%2C%20critical%20COVID-19%20patient-originating%20CoV-2-STs%20failed%20to%20expand%2C%20recapitulating%20the%20in%20vivo%20failure%20of%20CoV-2-specific%20T-cell%20immunity%20to%20control%20the%20infection.%20CoV-2-STs%20generated%20from%20asymptomatic%20PCR%2B%20individuals%20presented%20only%20weak%20responses%20whereas%20their%20counterparts%20originating%20from%20exposed%20to%20other%20seasonal%20coronaviruses%20subjects%20failed%20to%20kill%20the%20virus%2C%20thus%20disempowering%20the%20hypothesis%20of%20protective%20cross-immunity.Overall%2C%20we%20provide%20evidence%20on%20risk%20stratification%20of%20hospitalized%20COVID-19%20patients%20and%20the%20feasibility%20of%20generating%20powerful%20CoV-2-ST%20products%20from%20both%20convalescent%20and%20vaccinated%20donors%20as%20an%20%5Cu201coff-the%20shelf%5Cu201d%20T-cell%20immunotherapy%20for%20high-risk%20patients.%22%2C%22date%22%3A%22April%2027%2C%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciab371%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab371%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-29T16%3A57%3A51Z%22%7D%7D%5D%7D
Papayanni, P.-G., Chasiotis, D., Koukoulias, K., Georgakopoulou, A., Iatrou, A., Gavriilaki, E., Giannaki, C., Bitzani, M., Geka, E., Tasioudis, P., Chloros, D., Fylaktou, A., Kioumis, I., Triantafyllidou, M., Dimou-Besikli, S., Karavalakis, G., Boutou, A. K., Siotou, E., Anagnostopoulos, A., … Yannaki, E. (2021). Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients. Clinical Infectious Diseases, ciab371. https://doi.org/10.1093/cid/ciab371 Cite
